Last updated on November 2018

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab


Brief description of study

This trial is designed to determine what effects the human body has on the

investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with CD 20 positive B-cell non Hodgkin lymphoma.

This study will assess if the investigational medicine is safe and effective in treating CD 20 positive B-cell non Hodgkin lymphoma.

Clinical Study Identifier: NCT02747043

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Medellin, Colombia
5.08miles
  Connect »